A Phase I Study of an Anti-IDO1 Inhibitor (LY3381916) as Monotherapy and in Combination with an Anti-PD-L1 Antibody (LY3300054) in Patients with Advanced Cancer
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2019-12, Vol.30, p.xi41-xi42 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | xi42 |
|---|---|
| container_issue | |
| container_start_page | xi41 |
| container_title | Annals of oncology |
| container_volume | 30 |
| creator | Kotecki, N. O'Neil, B. Jalal, S. Massard, C. Wallin, J. Szpurka, A. Wang, D. Galvao, V. Regnier Xia, M.S. Crowe, K. Geeganage, S. Doman, T. Gandhi, L. Xu, X. Bendell, J. |
| description | |
| doi_str_mv | 10.1093/annonc/mdz451.021 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdz451_021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdz451_021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1331-43e62acc0cfef825d2b57f9de1260499d80a2f8eb7b17cad316e247c81e06e523</originalsourceid><addsrcrecordid>eNo9kL1OwzAUhT2ARCk8AJtHOoT62vnzGKX8RApqJWBgihzbUYyoXcUGVJ6GRyVtENO5y3fO1YfQFZAbIJwthbXOyuVWfccJ3BAKJ2hGOGVRlrD4DJ17_0YISTnlM_RT4E0vvMYVfgofao9dh4XFhQ0mqlZrwJXtTWuCG_B1_cpYDhzSBRYePzrrQq8HsduPhMLG4tJtW2NFMM7iLxP6_6bNKqrheLZu3Dg2jS8k8eKAbUZC2-AnplCfwkqtcHmI4QKdduLd68u_nKOXu9vn8iGq1_dVWdSRBMYgiplOqZCSyE53OU0UbZOs40oDTUnMucqJoF2u26yFTArFINU0zmQOmqQ6oWyOYOqVg_N-0F2zG8xWDPsGSHPQ2kxam0lrM2plv3HxbP0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Phase I Study of an Anti-IDO1 Inhibitor (LY3381916) as Monotherapy and in Combination with an Anti-PD-L1 Antibody (LY3300054) in Patients with Advanced Cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Kotecki, N. ; O'Neil, B. ; Jalal, S. ; Massard, C. ; Wallin, J. ; Szpurka, A. ; Wang, D. ; Galvao, V. Regnier ; Xia, M.S. ; Crowe, K. ; Geeganage, S. ; Doman, T. ; Gandhi, L. ; Xu, X. ; Bendell, J.</creator><creatorcontrib>Kotecki, N. ; O'Neil, B. ; Jalal, S. ; Massard, C. ; Wallin, J. ; Szpurka, A. ; Wang, D. ; Galvao, V. Regnier ; Xia, M.S. ; Crowe, K. ; Geeganage, S. ; Doman, T. ; Gandhi, L. ; Xu, X. ; Bendell, J.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>DOI: 10.1093/annonc/mdz451.021</identifier><language>eng</language><ispartof>Annals of oncology, 2019-12, Vol.30, p.xi41-xi42</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1331-43e62acc0cfef825d2b57f9de1260499d80a2f8eb7b17cad316e247c81e06e523</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Kotecki, N.</creatorcontrib><creatorcontrib>O'Neil, B.</creatorcontrib><creatorcontrib>Jalal, S.</creatorcontrib><creatorcontrib>Massard, C.</creatorcontrib><creatorcontrib>Wallin, J.</creatorcontrib><creatorcontrib>Szpurka, A.</creatorcontrib><creatorcontrib>Wang, D.</creatorcontrib><creatorcontrib>Galvao, V. Regnier</creatorcontrib><creatorcontrib>Xia, M.S.</creatorcontrib><creatorcontrib>Crowe, K.</creatorcontrib><creatorcontrib>Geeganage, S.</creatorcontrib><creatorcontrib>Doman, T.</creatorcontrib><creatorcontrib>Gandhi, L.</creatorcontrib><creatorcontrib>Xu, X.</creatorcontrib><creatorcontrib>Bendell, J.</creatorcontrib><title>A Phase I Study of an Anti-IDO1 Inhibitor (LY3381916) as Monotherapy and in Combination with an Anti-PD-L1 Antibody (LY3300054) in Patients with Advanced Cancer</title><title>Annals of oncology</title><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo9kL1OwzAUhT2ARCk8AJtHOoT62vnzGKX8RApqJWBgihzbUYyoXcUGVJ6GRyVtENO5y3fO1YfQFZAbIJwthbXOyuVWfccJ3BAKJ2hGOGVRlrD4DJ17_0YISTnlM_RT4E0vvMYVfgofao9dh4XFhQ0mqlZrwJXtTWuCG_B1_cpYDhzSBRYePzrrQq8HsduPhMLG4tJtW2NFMM7iLxP6_6bNKqrheLZu3Dg2jS8k8eKAbUZC2-AnplCfwkqtcHmI4QKdduLd68u_nKOXu9vn8iGq1_dVWdSRBMYgiplOqZCSyE53OU0UbZOs40oDTUnMucqJoF2u26yFTArFINU0zmQOmqQ6oWyOYOqVg_N-0F2zG8xWDPsGSHPQ2kxam0lrM2plv3HxbP0</recordid><startdate>201912</startdate><enddate>201912</enddate><creator>Kotecki, N.</creator><creator>O'Neil, B.</creator><creator>Jalal, S.</creator><creator>Massard, C.</creator><creator>Wallin, J.</creator><creator>Szpurka, A.</creator><creator>Wang, D.</creator><creator>Galvao, V. Regnier</creator><creator>Xia, M.S.</creator><creator>Crowe, K.</creator><creator>Geeganage, S.</creator><creator>Doman, T.</creator><creator>Gandhi, L.</creator><creator>Xu, X.</creator><creator>Bendell, J.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201912</creationdate><title>A Phase I Study of an Anti-IDO1 Inhibitor (LY3381916) as Monotherapy and in Combination with an Anti-PD-L1 Antibody (LY3300054) in Patients with Advanced Cancer</title><author>Kotecki, N. ; O'Neil, B. ; Jalal, S. ; Massard, C. ; Wallin, J. ; Szpurka, A. ; Wang, D. ; Galvao, V. Regnier ; Xia, M.S. ; Crowe, K. ; Geeganage, S. ; Doman, T. ; Gandhi, L. ; Xu, X. ; Bendell, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1331-43e62acc0cfef825d2b57f9de1260499d80a2f8eb7b17cad316e247c81e06e523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kotecki, N.</creatorcontrib><creatorcontrib>O'Neil, B.</creatorcontrib><creatorcontrib>Jalal, S.</creatorcontrib><creatorcontrib>Massard, C.</creatorcontrib><creatorcontrib>Wallin, J.</creatorcontrib><creatorcontrib>Szpurka, A.</creatorcontrib><creatorcontrib>Wang, D.</creatorcontrib><creatorcontrib>Galvao, V. Regnier</creatorcontrib><creatorcontrib>Xia, M.S.</creatorcontrib><creatorcontrib>Crowe, K.</creatorcontrib><creatorcontrib>Geeganage, S.</creatorcontrib><creatorcontrib>Doman, T.</creatorcontrib><creatorcontrib>Gandhi, L.</creatorcontrib><creatorcontrib>Xu, X.</creatorcontrib><creatorcontrib>Bendell, J.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kotecki, N.</au><au>O'Neil, B.</au><au>Jalal, S.</au><au>Massard, C.</au><au>Wallin, J.</au><au>Szpurka, A.</au><au>Wang, D.</au><au>Galvao, V. Regnier</au><au>Xia, M.S.</au><au>Crowe, K.</au><au>Geeganage, S.</au><au>Doman, T.</au><au>Gandhi, L.</au><au>Xu, X.</au><au>Bendell, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase I Study of an Anti-IDO1 Inhibitor (LY3381916) as Monotherapy and in Combination with an Anti-PD-L1 Antibody (LY3300054) in Patients with Advanced Cancer</atitle><jtitle>Annals of oncology</jtitle><date>2019-12</date><risdate>2019</risdate><volume>30</volume><spage>xi41</spage><epage>xi42</epage><pages>xi41-xi42</pages><issn>0923-7534</issn><doi>10.1093/annonc/mdz451.021</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2019-12, Vol.30, p.xi41-xi42 |
| issn | 0923-7534 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdz451_021 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | A Phase I Study of an Anti-IDO1 Inhibitor (LY3381916) as Monotherapy and in Combination with an Anti-PD-L1 Antibody (LY3300054) in Patients with Advanced Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T20%3A13%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%20I%20Study%20of%20an%20Anti-IDO1%20Inhibitor%20(LY3381916)%20as%20Monotherapy%20and%20in%20Combination%20with%20an%20Anti-PD-L1%20Antibody%20(LY3300054)%20in%20Patients%20with%20Advanced%20Cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Kotecki,%20N.&rft.date=2019-12&rft.volume=30&rft.spage=xi41&rft.epage=xi42&rft.pages=xi41-xi42&rft.issn=0923-7534&rft_id=info:doi/10.1093/annonc/mdz451.021&rft_dat=%3Ccrossref%3E10_1093_annonc_mdz451_021%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |